DELCATH SYSTEMS, INC. (NASDAQ:DCTH) Files An 8-K Changes in Registrant’s Certifying AccountantItem 4.01.
On April3, 2018, the Audit Committee (the “Audit Committee”) of the Board of Directors of Delcath Systems, Inc., a Delaware corporation (the “Company”), approved the engagement of Marcum LLP (“Marcum”) as the Company’s independent registered public accounting firm for the Company’s fiscal year ended December31, 2018, and the dismissal of Grant Thornton LLP (“Grant Thornton”) as the Company’s independent registered public accounting firm.
Grant Thornton’s audit reports on the Company’s consolidated financial statements as of and for the fiscal years ended December31, 2017 and 2016 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that the report included an explanatory paragraph describing the existence of conditions that raise substantial doubt about the Company’s ability to continue as a going concern.
During the fiscal years ended December31, 2017, and 2016, and the subsequent interim periods through April 9, 2018, there were (i)no disagreements (as described in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and Grant Thornton on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to Grant Thornton’s satisfaction, would have caused Grant Thornton to make reference thereto in their reports on the financial statements for such years, and (ii)no “reportable events” within the meaning of Item 304(a)(1)(v) of Regulation SK.
The Company provided Grant Thornton with a copy of the disclosures it is making in this Current Report on Form 8-K and requested that Grant Thornton furnish a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the statements made herein. A copy of Grant Thornton’s letter, dated April 9, 2018, is filed as Exhibit 16.1 hereto.
During the fiscal years ended December31, 2017, and 2016, and the subsequent interim periods through April 9, 2018, neither the Company nor anyone acting on its behalf has consulted with Marcum regarding (i)the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements or the effectiveness of internal control over financial reporting, and neither a written report or oral advice was provided to the Company by Marcum that was considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue, (ii)any matter that was the subject of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K, or (iii)any reportable event within the meaning of Item 304(a)(1)(v) of Regulation S-K.
(d) Exhibits
DELCATH SYSTEMS, INC. ExhibitEX-16.1 2 d533632dex161.htm EX-16.1 EX-16.1 Exhibit 16.1 April 9,…To view the full exhibit click here
About DELCATH SYSTEMS, INC. (NASDAQ:DCTH)
Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.